Evolent Health Inc-A 2024年度报告

(Mark One) SANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year endedDecember31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromto Commission File Number:001-37415_________________________ Evolent Health, Inc.(Exact name of registrant as specified in its charter) _________________________ Delaware(State or other jurisdiction ofincorporation or organization) 1812 N. Moore Street,Suite 1705,Arlington,Virginia22209(Address of principal executive offices)(Zip Code) (571)389-6000Registrant’s telephone number, including area code_________________________ Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registere Class A Common Stock of Evolent Health, Inc., par value$0.01 per shareEVHNew York Stock Exchange Securities registered pursuant to section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.YesSNo☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐NoS Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.YesSNo☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).YesSNo☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company.See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerSAccelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness ofits internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered publicaccounting firm that prepared or issued its audit report.S If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrantincluded in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐NoS The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant (based on the closing priceof the shares on the New York Stock Exchange on such date) as of the last business day of the registrant’s most recently completed secondfiscal quarter was $2.2billion. As of February14, 2025, there were116,591,148shares of the registrant’s Class A common stock outstanding. Documents Incorporated by Reference Selected portions of the Proxy Statement for the Annual Meeting of Stockholders, scheduled for June5, 2025, have been incorporated byreference into Part III of this Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and ExchangeCommission within 120 days of the registrant’s fiscal year ended December31, 2024. Evolent Health, Inc.Table of Contents Item PART I 1.Business1A.Risk Factors1B.Unresolved Staff Comments1CCybersecurity2.Properties3.Legal Proceedings4.Mine Safety Disclosures PART II 5.Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities6.Reserved7.Management’s Discussion and Analysis of Financial Condition and Results of Operations7A.Quantitative and Qualitative Disclosures About Market Risk8.Financial Statements and Supplementary Data9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure